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Abstract
Background: Mutations in three functionally diverse genes cause Rett Syndrome. Although the functions of
Forkhead box G1 (FOXG1), Methyl CpG binding protein 2 (MECP2) and Cyclin-dependent kinase-like 5 (CDKL5) have
been studied individually, not much is known about their relation to each other with respect to expression levels
and regulatory regions. Here we analyzed data from hundreds of mouse and human samples included in the
FANTOM5 project, to identify transcript initiation sites, expression levels, expression correlations and regulatory
regions of the three genes.
Results: Our investigations reveal the predominantly used transcription start sites (TSSs) for each gene including
novel transcription start sites for FOXG1. We show that FOXG1 expression is poorly correlated with the expression
of MECP2 and CDKL5. We identify promoter shapes for each TSS, the predicted location of enhancers for each gene
and the common transcription factors likely to regulate the three genes. Our data imply Polycomb Repressive
Complex 2 (PRC2) mediated silencing of Foxg1 in cerebellum.
Conclusions: Our analyses provide a comprehensive picture of the regulatory regions of the three genes involved
in Rett Syndrome.
Keywords: Rett Syndrome, CAGE, Transcriptomics, Promoter architecture
Background
Rett Syndrome (RTT) is a disorder caused by mutations in
Methyl CpG binding protein 2 (MECP2), Forkhead box
G1 (FOXG1) or Cyclin-dependent kinase-like 5 (CDKL5)
genes [1-3] Although the phenotype of patients with mu-
tations in MECP2 differs from the phenotype of patients
with FOXG1 or CDKL5 mutations, there are some similar-
ities in the clinical profile that overlap with RTT. Classic
RTT patients with MECP2 mutations have a normal
period of development followed by regression of acquired
skills, deceleration of head circumference, epilepsy, hand
stereotypies, breathing abnormalities, inability to walk or
talk and intellectual disability while patients with atypical
RTT may show some but not all features of classic Rett
syndrome [4]. Mutations in FOXG1 are known to cause
the congenital variant of Rett syndrome where the
initial normal developmental window is absent [2].
CDKL5 mutations are found in patients with severe
epilepsy during early childhood that later show fea-
tures that resemble atypical RTT syndrome [5].
MeCP2 is an X-linked methyl CpG binding protein which
binds methylated and unmethylated DNA [6-9] and func-
tions as a repressor and activator of genes [10-13]. Even
thoughMECP2 is expressed ubiquitously [14], MECP2 mu-
tations and copy number variations in humans lead to
neurological phenotypes such as classic or atypical Rett
syndrome and in rare cases Angelman Syndrome, X-linked
mental retardation and Autism (reviewed in [15]) suggest-
ing a distinct role for MeCP2 protein in the brain [16,17].
The level of MeCP2 protein in neurons increases with
neuronal maturity [18] and it is abundantly expressed in
the mature brain, almost equivalent to Histone H1 levels
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[19], but the level of MECP2 mRNA in cells is reported to
not correlate with the level of MeCP2 protein in cells [18].
FOXG1 protein is a brain specific member of the
forkhead transcription factor family with a role in
transcriptional repression. Similar to other members
of the forkhead family, FOXG1 has a defined binding
sequence motif [20], which bears sequence similarity
to other forkhead protein binding sites.
CDKL5 protein is a serine threonine kinase, whose
expression is low in embryonic stages, but increases in
postnatal stages up to postnatal day 15 [21] CDKL5
mRNA is expressed in brain and all other tissues [22,23].
CDKL5 protein levels are known to coincide with its
mRNA levels [24].
Even though these three genes have different expression
patterns, distinct functions and specific regulatory targets,
their paths appear to intersect. Both MeCP2 and FOXG1
proteins regulate transcription via DNA binding and
association with other transcriptional regulators [6-13]
[25,26]. The functions of MeCP2 and CDKL5 proteins
also appear to be interconnected. MeCP2 has multiple
phosphorylation sites [27] and is a target of CDKL5
phosphorylation. Additionally, there are contradictory
reports on the expression level of CDKL5 protein and
mRNA in the absence of MeCP2 [28-30]. Altogether,
these observations suggest that the overlapping fea-
tures in Rett syndrome may be caused by impairment
of common or intersecting biological pathways down-
stream of expression in the brain. Alternately, these
genes may be interdependent on each other for expression
or regulation, which may lead to the overlap in phenotypic
features.
Although we have some knowledge of their downstream
intersecting functions, we are yet unaware of the common
genomic features between these three genes, which
may provide insights into their regulation. Importantly,
although both MECP2 and CDKL5 genes are expressed
ubiquitously, their mutations cause a brain specific pheno-
type suggesting that their expression level, transcription
regulation, or function in brain may be distinct from that
in other tissues. We tried to resolve these questions
through bioinformatics analyses using the FANTOM5
dataset [31].
Data from FANTOM5 provide the unprecedented
opportunity to identify the transcription start sites
(TSSs) of these genes and study their expression profile in
hundreds of mouse and human samples using Cap
Analysis of Gene Expression method (CAGE) [31]. In
conjunction with the recently released ENCODE dataset
[32]. FANTOM5 data also enable the identification of
regulatory histone marks at TSSs. Since the RTT pheno-
type is reflected in the Mecp2 KO mouse model [33] and
studies on this disorder are conducted in mouse tissues
and cells, we also included mouse samples in our analyses.
We analyzed the TSS expression data from the FANTOM5
project using over 1000 human and over 450 mouse
samples to identify common and diverse features of the
genomic architecture of the three genes implicated in RTT
(for a complete list of samples Additional file 1: Table S1).
For our investigation, we divided the human and mouse
samples into tissues, primary cells and cell lines to study
the expression levels of the TSS of the three genes in
various samples. Our data reveal the precise initiation
sites for the three genes, including previously unknown
TSSs for FOXG1 in mouse and humans. We show that
each of these genes use the same TSS in most tissues and
provide information on the expression level of the three
genes over development in multiple human and mouse
samples. Although we did not find a significant correlation
between the expression levels of the three genes in the
brain, our genome wide analyses uncovered common
transcription factors regulating the three genes, suggesting
an additional molecular layer in the pathogenesis of Rett
Syndrome. The FANTOM5 CAGE dataset also allowed us
to locate putative enhancers regulating the three genes in
human (methods described in Anderson et al., [34]) and
using mouse ENCODE ChIP-seq data, we identified
genomic regions bearing promoter and enhancer marks.
This work is part of the FANTOM5 project. Data down-
loads, genomic tools and co-published manuscripts are
summarized here: http://fantom.gsc.riken.jp/5/.
Methods
FANTOM5 samples
Single molecule CAGE profiles were generated from
RNA obtained from a collection of 573 human primary cell
samples (~3 donors for most cell types) covering most
mammalian cell steady states. This data set was comple-
mented with profiles of 250 different cancer cell lines, 152
human post-mortem tissues and 456 mouse samples
(detailed sample list is available in Additional file 1: Table S1
and origin of each sample is available as Supplementary
Material in Forrest et al. 2014 [31]). Primary cells for
neurons and astrocytes discussed in this manuscript
were obtained from ScienCell Research Laboratories.
Human neurons were isolated from the human brain,
cryopreserved at primary cultures and delivered frozen.
Human astrocytes were isolated from cerebral cortex and
cerebellum. Both were cryopreserved at passage one and
delivered frozen.
All human samples used in the project were either
exempted material (available in public collections or com-
mercially available), or provided under informed consent.
All non-exempt material is covered under RIKEN
Yokohama Ethics applications (H17-34 and H21-14). Mouse
tissue samples were collected as per RIKEN Yokohama
institutional guidelines. Mouse primary cells were collected
as per our collaborators Institutional guidelines and
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shipped as either purified RNA or as guanidinium
isothyocyanate lysates (Trizol, Isogen or Qiazol) which
were then purified using the miRNeasy kit (QIAGEN).
More detailed information for each specific sample is
available in Additional file: 1 Table S1 of [31].
All the data published by the Fantom5 project and by
this study are available through the Fantom5 portal
http://fantom.gsc.riken.jp/5/data/. All CAGE data has
been deposited at DDBJ DRA under accession number
DRA000991.
Identifying CAGE derived transcription start sites
We used the FANTOM5 database ([31]) to identify
transcription start sites (TSS) for our genes, using the
decomposition peak identification (DPI) clustering and
nomenclature developed for the FANTOM5 project [31].
We selected robust CAGE defined DPI clusters falling
inside the RefSeq regions known to be associated to the
three genes. To select for genuine TSSs we used the
FANTOM5 TSS classifier and restricted our TSS selection
to those with a value of 0.1 and above [31]. The TSSs were
annotated using the names assigned to clusters in the
FANTOM5 Resource browser (SSTAR, Semantic catalogue
of, samples, transcription initiations, and regulations,
http://fantom.gsc.riken.jp/5/sstar/). Annotation files were
built in the context of the FANTOM5 project with respect
to Gencode v10 gene model (human), RefSeq (mouse),
CpG islands and TATA box in bed format.
TSS expression
We extracted expression information for each TSSs
using the FANTOM5 expression dataset for tissues,
cell lines and primary cells in human and mouse (see
Additional file 1: Table S1 for a full list of samples
and TPM expressions). The expression values are shown
in tags per million (TPM) calculated on a per-library total
expression. We discarded all the TSSs that did not
have over 5 TPM expression in any of the samples.
All expression level figures, heatmaps and correlations
were calculated using R (http://www.r-project.org/).
Mecp2 and histone expression comparison
We extracted the CAGE defined promoters associated
to the genes whose products form the Histone1 tran-
scripts (HIST1H1A, HIST1H1B, HIST1H1C, HIST1H1D,
HIST1H1E, H1F0, H1FX). All the values for different
genes were added together and compared to expression
levels of MECP2.
Identifying TSS overlaps with ChIP seq data from human
and mouse ENCODE TSSs
TSSs identified were expanded by 500 nucleotides on
either side (±500bp). ChIP seq data from Human and
mouse ENCODE were downloaded as bed files and inter-
sected with our expanded TSS using intersectBed [35].
Defining human enhancers
To identify enhancers associated with the human Rett
genes, we used the CAGE derived enhancer database from
Andersson et al. [34]. In short, the identified enhancers
from Andersson et al. within 500kb distance from the iden-
tified Rett genes promoters were selected [34]. The expres-
sion of pairs of enhancers and promoters was then
compared in all the human samples using a Pearson correl-
ation test. The resulting comparisons were then corrected
for multiple testing using Bonferroni correction. Only
enhancers significantly correlated (corrected P < 0.05)
with any of the three Rett genes promoters were
included.
Transcription factor binding site (TFBS) analysis
We downloaded the whole-genome alignment of the
human genome with 45 other vertebrate genomes,
and of the mouse genome with 29 other vertebrate
genomes, from the UCSC Genome Browser database
[36]. From these alignments, we retained the alignments
between the human, macaque, mouse, rat, cow, horse,
dog, opossum, and chicken genomes only, and used the
T-Coffee alignment tool [37] on 1000 bp segments of
the genome to optimize the alignment for the nine
selected genomes. We then ran MotEvo [38] on these
whole-genome alignments using a background prior
probability of 0.98, a prior for the UFE (unidentified
functional element) model of 200 relative to the weight
matrices, a UFE motif length of 8 base pairs, and a
uniform background sequence probability. A posterior
probability calculated by MotEvo for a putative TFBS
was retained if it was at least 0.2. We used the center
position for a given CAGE promoter on the genome as a
reference point, and summed the posterior probabilities
for the putative binding sites for each transcription factor
within a distance of 500 basepairs of the reference point
to obtain the estimated number of binding sites for each
transcription factor. To evaluate the statistical significance
of this number, for each transcription factor we estimated
the number of binding sites in exactly the same way for all
184,827 (human) or 116,227 (mouse) promoters in
the FANTOM5 data sets, and ranked the promoters
accordingly. The tail probability was then obtained by
dividing the rank of the promoter of interest by 184,827
(human) or 116,227 (mouse).
Results
FOXG1 expression in mouse and humans
Analyses of TSS from 1193 human samples and 457
mouse samples comprised of tissues, primary cells and
cell lines (only one mouse cell line was investigated in
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FANTOM5) identified 8 TSSs for human FOXG1 and 6
TSSs for mouse Foxg1 (Additional file 2: Table S2).
FOXG1 expression above 1 TPM was found in 23% (231)
and 30% (140) of human and mouse samples respectively,
suggesting that the expression of this gene was limited to
selected tissues (Additional file 1: Table S1). Transcription
start sites were defined as novel if they were found at a
distance of over 500 bp from the known RefSeq TSSs.
Our data show 3 TSSs in mouse highly expressed in brain
sub-regions and cells, two of which are novel. The expres-
sion levels of different TSSs of FOXG1 were variable in
human and mouse samples, with the highest expression
seen in specific regions of the brain (Figures 1a, b,
Additional file 3: Figures S1a,b). The top three initiation
sites were located at (in order of their expression levels)
chr12:50484904..50484950,+; (pA@Foxg1, novel promoter,
located more than 1000 bases downstream of the RefSeq
annotated TSSs) chr12:50483639..50483654,+; (p1@Foxg1,
200 bp upstream of the two annotated Foxg1 TSSs) and
chr12:50485112..50485144,+;(pB@Foxg1, novel promoter,
1200 bp downstream from the annotated RefSeq initiation
sites) (Figure 2a). Expression of mouse Foxg1 was also
restricted to brain tissue and brain related cells, but
surprisingly the two novel TSSs of mouse Foxg1 were
also found highly expressed in the single mouse cell
line sequenced in the FANTOM5 project (fibroblast
cell line) suggesting that other than the brain, fibroblast
cell lines may be useful for in vitro analysis of Foxg1 in
mouse (Figure 1a).
In human, there is RefSeq annotation support for a
single FOXG1 isoform and therefore a single TSS. We
found 8 TSSs for human FOXG1 expressed over 5 TPM
and the 3 TSSs with the highest expression in human brain
were located at chr14:29235961..29236008,+ (p1@FOXG1);
chr14:29234581..29234601,+ (p2@FOXG1; novel); and
chr14:29236269..29236285,+ (p3@FOXG1), with distances
of 317, 1697 and 9 bases upstream of the RefSeq annotated
TSS, respectively (Additional file 2: Table S2, Figure 2d,
Additional file 3: Figure S1). Thus, our analyses reveal that
in human brain the highest used TSS for FOXG1 is lo-
cated 317 bases upstream of the annotated start site.
Contrary to mouse, where we found expression level
differences of over 10-fold between TSSs, in human
samples, the difference in expression between the three
TSSs was less than 2-fold (Figure 1a, 1b, Additional file 1:
Table S1).
Intriguingly, we did not find FOXG1 expression in
mouse or human cerebellum suggesting silencing of
FOXG1 in cerebellum. Inability to detect TSS expression
may result from technical artifacts such as low expression
levels not discernible at the conducted depth of sequencing
or the use of an alternate tissue specific start site. To rule
out technical artifacts, we referred to the ENCODE dataset
to investigate signs of transcriptional activity in the
chromosomal location of Foxg1 and up to 10 kb upstream
in mouse cerebellum. We analyzed ENCODE data for
DNAse-I hypersensitive sites (DNAse-I HSS), which are
known to faithfully recognize active transcription initiation
sites [39], in mouse cerebellum, cerebrum and whole brain.
Our analyses revealed an absence of DNAse-I HSS in
mouse cerebellum, while DNAse-I HSS were present in
cerebrum and whole brain samples (Additional file 4:
Figure S2). Since DNAse-I HSS usually coincide with
the active promoter specific histone mark of trimethylated
Histone 3 lysine 4 (H3K4me3) [39] and transcriptionally
active enhancers may also bear the specific histone mark
of acetylated Histone 3 lysine 27 (H3K27ac), we looked
for these two marks in mouse cerebellum and mouse
cortex. We found that H3K4me3 and H3K27ac were
enriched at the locus in 8-week old cortex samples, but
not in 8-week old cerebellum samples. Surprisingly,
our investigations revealed trimethylated Histone 3 lysine
27 (H3K27me3) enrichment at this chromosomal locus in
mouse cerebellum, suggesting silencing of Foxg1 by Poly-
comb Repressive Complex 2 (PRC2) (Additional file 4:
Figure S2). Since ChIP data for active and repressive
histone marks in human brain is not available from
ENCODE at this time, we were unable to confirm
similar chromatin signatures for PRC2 silencing of
FOXG1 in the human cerebellum.
Silencing by chromatin remodeling proteins such as
PRC2 requires a non-coding RNA to mediate chromatin
modification [40]. Therefore, we searched for potential
cis-regulatory ncRNAs that may mediate Foxg1 silencing.
We found one ncRNA downstream of Foxg1 (RefSeq
NR_026733), however its expression was not entirely
discordant with that of Foxg1 (data not shown). Analysis
of the ncRNA database and manual annotation of UCSC
Genome Browser revealed several ncRNAs within a
genomic window of 1.5 MB around Foxg1, but none
of the listed ncRNAs were detectable in the FANTOM5
CAGE dataset.
MECP2 expression in mouse and humans
In humans and mouse we identified two TSSs for MECP2,
less than 100 bases upstream of the RefSeq annotated start
sites of which p1@MECP2/Mecp2 was expressed predom-
inantly in most tissues and p2@MECP2/Mecp2 displayed
a stable low level expression in all tissues (expression less
than 10 TPM) (Additional file 2: Table S2, Figures 1c, 1d,
2b and 2e). We found an additional intronic promoter
(p5@MECP2) in humans alone, expressed exclusively in
blood primary cells, particularly in CD14 monocytes
(Figure 1d and Figure 2e). Expression of p1@MECP2
in humans and mouse was found above 5 TPM in most
tissues, primary cells and cell lines, suggesting that tran-
scripts arising from this promoter were ubiquitously
expressed. Surprisingly our analysis of human tissues and
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cells revealed that the highest expression of MECP2
was seen in non-neuronal tissues (vagina and ovary)
and cell lines (Breast Carcinoma, Krukenberg tumour, lens
epithelial and lung adenocarcinoma) (Additional file 3:
Figure S1d). In agreement with previous reports in mouse,
we found that at mRNA level, the expression of p1@Mecp2
in astrocytes (15 TPM) was much lower than in neurons
(77 to 41 TPM) (Additional file 3: Figure S1c) but among
human primary cells, the expression of p1@MECP2 in
neurons (12 TPM) was lower than the p1@MECP2
expression in astrocytes (34 TPM). In contrast with
the brain, the expression levels of MeCP2 protein in
the heart are reportedly higher in embryonic stages
than in postnatal heart [41]. Therefore, we investigated
the expression levels of Mecp2 during development in
heart, liver and kidney. Our analyses showed that in heart,
Mecp2 expression fluctuated during embryonic stages and
was higher than at postnatal day 25 (P25) and P30. In
kidney, the expression of Mecp2 declined after P20 and in
liver the expression ofMecp2 appeared to be induced after
birth (P00) but remained unstable up to the age of P30
(Additional file 5: Figure S3a-c).
CDKL5 expression in Humans and Mouse
The RefSeq database annotates one TSS for CDKL5 in
mouse and two TSSs in human (Additional file 2: Table S2).
Our analyses identified two TSSs within 100 bp of the
annotated TSS in mouse and the upstream TSS in
human samples (p1@CDKL5/Cdkl5 and p2@CDKL5/
Cdkl5, Figures 2c and 2f ). In both human and mouse
samples, CDKL5 expression was higher in brain tissues
than in primary cells or cell lines (Figure 1e and 1f). The
two TSSs of CDKL5 were co-expressed ubiquitously in
human and mouse, however p1@CDKL5 was expressed
more than p2@CDKL5 in most tissues in humans suggest-
ing that transcripts arising from p1@CDKL5 may be
over-represented in humans (Figure 1e and 1f). In mouse
p1@Cdkl5 and p2@Cdkl5 were expressed at similar levels
in some brain sub-regions. We tracked the expression of
Cdkl5 in mouse heart, liver and kidney over development
Figure 2 Locations of the TSSs identified for the three genes. Genome browser images showing all the TSSs identified in this study for
FOXG1 (panels a and d), MECP2 (panels b and e) and CDKL5 (panels c and f) in mouse (panels a,b and c) and humans (panels d, e and f).
In each panel the top two tracks show RefSeq genes and mRNAs from Genbank. The third track shows FANTOM5 TSS and the bottom track shows
CpG islands. Red arrows mark the key TSSs for each gene. We found 6 TSSs for Foxg1 in mouse (panel a) and 8 TSSs in humans (panel d). Novel TSSs
are identified by asterisks. We also found a CD14 specific intronic TSS p5 for MECP2 in human cells.
(See figure on previous page.)
Figure 1 Expression levels of the identified TSS for the three genes. Dot plots showing the expression level of each promoter in TPM values
in all brain regions, and selected other samples (based on expression level). The novel promoter pA@Foxg1 is the most highly expressed Foxg1
TSS in mouse primary cells and brain tissue (a), with the highest expression in cortical neurons (1018 TPM) and neonate hippocampus (435 TPM).
Among mouse cells, we find high levels of p1@ Foxg1 expressed in hippocampal neurons and fibroblast cell line. In human samples (panel b)
the highest expression of FOXG1 is seen from p1@FOXG1 in fetal temporal lobe (292 TPM), among primary cells in neurons (149 TPM) and
among cell lines in medulloblastoma cell line (184 TPM). For mouse Mecp2, the highest expression of p1@Mecp2 is in striatal neurons (77 TPM)
and cerebellar granule cells (70 TPM) and among mouse tissues (panel c) the maximum expression is seen in neonate corpus striatum (65 TPM)
and adult cerebellum (52 TPM). For human, the highest expression of p1@MECP2 is found in cancer cell lines including breast carcinoma cell line
(119 TPM) (panel d). In human brain the highest expression of p1@MECP2 is found in the temporal lobe (63 TPM). The two promoters of Cdkl5 in
mouse are co-expressed with highest expression in adult cortex in the brain and raphe neurons among primary cells (panel e). In humans (panel f)
the two promoters are expressed differentially with transcripts arising from p1 over-represented. p1@CDKL5 expression is highest in the newborn
medial frontal gyrus and in neurons. In human cancer cell lines, CDKL5 is generally expressed at low levels (less than 10 TPM) from either of the
promoters (p1 > p2), with a few exceptions (Additional file 1: Table S1, Additional file 3: Figure S1f).
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from embryonic day 11 to postnatal day 30. These tissues
were previously reported to have undetectable levels of
Cdkl5 [22,23]. In heart, the expression levels of Cdkl5
fluctuated up to P30 (Additional file 5: Figure S3d
p1@Cdkl5 p2@Cdkl5 heart). In liver and kidney,
Cdkl5 expression from both TSSs was lower in adult
(P25 and P30) than embryonic tissues (Additional file
5: Figure S3e,f ). This observation was in contrast to
the brain where the expression of Cdkl5 was generally
higher in postnatal brain in both mouse and humans
(Additional file 6: Figure S5e,f). In agreement with pub-
lished data [21] we found restricted expression of Cdkl5 in
mouse astrocytes (maximum 2 TPM, Additional file 3:
Figure S1e).
Developmental profile for the three genes in brain sub
regions
The expression levels of FOXG1, MECP2 and CDKL5 are
developmentally regulated in the brain. FOXG1 expression
is reported to be highest during early embryogenesis
[2,42,43]. CDKL5 is weakly expressed during embryogen-
esis in the cortex and its expression increases in postnatal
stages until P14 after which CDKL5 expression is dimin-
ished [21,24]. MeCP2 protein levels in the brain increase as
development proceeds stabilizing around postnatal day 5
[19]. We investigated if the reported developmental expres-
sion profile for the three proteins was reflected at the TSS
level. For mouse, we investigated the developmental TSS
expression of Mecp2 and Cdkl5 in the cerebellum (n = 3 at
each age), pituitary cortex (n = 1 at each age) and visual
cortex (n = 4 at P15 and n= 3 at P30 and P60). Our data re-
veal that p1@Mecp2 expression fluctuates in embryonic
cerebellum samples but is clearly induced after postnatal day
9 (Additional file 7: Figure S4). The expression of p1@Cdkl5
and p2@Cdkl5 in mouse closely resemble the pattern of
expression of p1@Mecp2 but at lower levels. These data are
in agreement with protein expression levels of Cdkl5 and
Mecp2 reported previously in cerebellum by Rusconi et al.
[21]. In visual cortex samples, where we investigated a
broader time course we found a striking resemblance of
expression pattern between p1@Mecp2 and p2@Cdkl5 with
both genes showing an increase from P14 to P30 and stabil-
izing from P30 to P60, while the expression of p1@Cdkl5
remained steady. In contrast, the expression of pA@Foxg1
decreased as visual cortex matured (Additional file 7:
Figure S4b). Similarly, in the pituitary gland, we found the
expression of Cdkl5 and Mecp2 to fluctuate during embry-
onic stages, while Foxg1 displayed high expression during
embryonic stages with lowest expression in adult.
In broad time-course samples of fetal, neonate and
adult human brain sub-regions we found that FOXG1
expression was generally higher in fetal samples
(Additional file 6: Figure S5a) while the expression
of both promoters of CDKL5 and p1@MECP2 in fetal
samples were lower than their expression level in adults
(Additional file 6: Figure S5b,c).
Comparison between Mecp2 and Histone H1 expression
level in neurons
Skene et al. previously showed that in wild-type mouse
neurons, the density of MeCP2 protein is one molecule
per two nucleosomes - equal to that of Histone H1,
which is also one molecule per two nucleosomes [19].
We investigated whether the similarity between Mecp2
and Histone H1 protein density was reflected at the
mRNA level in human and mouse neurons. We also
compared the expression level of Histone H1 and Mecp2
TSS in brain sub regions even though Skene et al. [19]
had not reported a correlation between the levels of the
two proteins in whole brain tissue (they reported a correl-
ation only in neuronal nuclei). We extracted the expression
for all H1 transcripts and compared their individual and
collective levels to p1@MECP2 expression in both human
and mouse. The primary cells in mouse included neurons
from various brain sites as well as astrocytes and microglia
cells. Our data show that the combined as well as individual
expression levels of all histone H1 transcripts were much
higher than the expression levels of p1@Mecp2 at all ages
in all samples (Additional file 8: Figure S6). In raphe
neurons, substantia nigra neurons (E14), ventral spinal cord
neurons (E14) and hippocampal astrocytes, we found the
expression level of a few histone transcripts closer to the
expression level of Mecp2 (Additional file 9: Table S3).
Overall, this is interesting, because in order to reconcile this
with the findings of Skene et al., substantial changes
in either protein production or decay of MeCP2 and/or
the Histone 1 proteins must occur to offset the mRNA
steady state.
Intra gene and Inter gene expression correlations
between FOXG1, CDKL5 and MECP2 in brain sub-regions
To investigate the relationship between the expression
of all TSSs of each gene, we conducted intra gene corre-
lations and found a high degree of correlation between
p1@FOXG1 and p3@FOXG1 in human samples and
between the promoters pA@Foxg1, pB@Foxg1, p1@Foxg1
and p2@Foxg1 in mouse (Table 1, Additional file 10: Table
S4, Additional file 11: Figure S7). The two TSSs ofMECP2
were moderately but positively correlated with each other
in humans and mouse, while the two TSSs of Cdkl5
were highly correlated in mouse (correlation coefficient,
Spearman’s rank correlation 0.85) confirming our earlier
observation of similarities in expression of the two Cdkl5
promoters in mouse.
Since mutations in the MECP2, FOXG1 and CDKL5
genes result in overlapping neurological phenotypes, we
additionally investigated the inter gene expression correla-
tions of the three genes in the brain. We first generated
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heatmaps from all brain sub-regions and brain related pri-
mary cells (Figure 3a and b) for the three genes. We found
that in humans and mouse the expression of p1@FOXG1
and pA@Foxg1 in brain was strikingly discordant with the
expression of p1@MECP2 and p1@Mecp2 respectively
(Figure 3a, 3b). Next, we investigated the correlation
between the highly expressed promoters of the three
genes using Spearman’s rank test and Pearson’s correlation
coefficients. Based on our earlier heatmap visualization of
contrasting expression of MECP2 and FOXG1 in brain
tissue, we expected to see a negative correlation between
the promoters of these genes in both species. Our data
generated from all brain tissues, neurons and astrocytes
showed that in mouse the correlation between pA@Foxg1
and p1@Mecp2 expression was poor (0.3) and in humans
we found negative correlation of −0.1, suggesting slight
discordance of expression of the two genes in brain. Thus,
our analyses failed to find mathematically significant
evidence of contrasting expression between FOXG1 and
MECP2. The two promoters of CDKL5 were also poorly
correlated with the FOXG1 promoter expression in brain,
while there was a positive correlation (23-49%) between
expression of MECP2 and CDKL5 in both species
(Figures 3c - 3f, Additional file 11: Figure S7).
Identification of regulatory regions of the three genes
To identify the regulatory regions associated with the TSS
of the three genes in mouse, we extended our TSS co-
ordinates by 500bp on either side and intersected them
with active histone regulatory marks of H3K27ac and
H3K4me3 from ENCODE datasets. Based on current lit-
erature [44-47], on chromatin modifications marking
active enhancers and promoters, we defined the cri-
teria for active enhancers as those regions carrying the
H3K27ac mark and active promoters as those regions car-
rying the H3K4me3 without complete overlap with the
H3K27ac mark.
Since all three genes were found highly expressed in the
cortex, we used ENCODE ChIP tracks for 8 week old
cortex for this analysis. Based on our results we derived
gene models for the three genes in mouse cortex (Figure 4).
Our data revealed that the investigated regulatory marks
for mouse Foxg1, were distinct and non-overlapping
(Additional file 12: Table S5). We found that the main TSSs
pA@Foxg1 and pB@Foxg1 were located between an en-
hancer specific histone mark upstream and a promoter spe-
cific histone mark downstream (Figure 4a and Additional
file 12: Table S5). In contrast, for Mecp2, we found the
enhancer and promoter specific histone marks to co-
incide in this tissue (Figure 4b, Additional file 12:
Table S5). The Mecp2 TSSs p1@Mecp2 and p2@Mecp2
were upstream but within 500 bp of the histone spe-
cific marks for enhancer and promoter. For Cdkl5, we
found a partial overlap between enhancer and promoter
specific histone marks. The p1@Cdkl5 was located within
the promoter specific histone mark while the enhancer
specific histone mark was found upstream (Figure 4c,
Additional file 12: Table S5). The TSS p2@Cdkl5 was also
located within 500 bp of these marks.
As a complementary analysis, we identified human en-
hancers for the three genes using the database provided in
[34] that predicts active enhancers based on the expression
of balanced bi-directional low expressed enhancer RNA
transcripts. For FOXG1, MECP2 and CDKL5, we found
Table 1 Spearman Rank Correlations between the key promoters of the three genes in mouse (A) and human (B)
A: Correlation between promoters in mouse samples
pA@Foxg1 pB@Foxg1 p1@Foxg1 p1@Mecp2 p1@Cdkl5 P2@Cdkl5
pA@Foxg1 1.00 0.77 0.76 0.35 0.24 0.29
pB@Foxg1 0.77 1.00 0.83 0.32 0.22 0.26
p1@Foxg1 0.76 0.83 1.00 0.30 0.21 0.24
p1@Mecp2 0.35 0.32 0.30 1.00 0.49 0.56
p1@Cdkl5 0.24 0.22 0.21 0.49 1.00 0.85
P2@Cdkl5 0.29 0.26 0.24 0.56 0.85 1.00
B: Correlation between promoters in human samples
P1@FOXG1 P2@FOXG1 P3@FOXG1 p1@MECP2 p1@CDKL5 P2@CDKL5
P1@FOXG1 1.00 0.75 0.81 0.06 0.23 0.20
P2@FOXG1 0.75 1.00 0.77 0.08 0.30 0.26
P3@FOXG1 0.81 0.77 1.00 0.06 0.24 0.22
p1@MECP2 0.06 0.08 0.06 1.00 0.23 0.27
p1@CDKL5 0.23 0.30 0.24 0.23 1.00 0.73
P2@CDKL5 0.20 0.26 0.22 0.27 0.73 1.00
See Additional file 9: Table S4 for a complete list.
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4, 14 and 1 significantly correlated cis-enhancers re-
spectively (Additional file 13: Table S6, Additional file 14:
Figure S8). In contrast to the mouse cortex data, the pre-
dicted enhancers in human samples were found kilo bases
away from each gene suggesting long-range complex regu-
lation of the three genes in humans. For FOXG1 the most
highly correlated enhancer (r = 0.78) was located 7kb up-
stream of the gene. Many predicted enhancers for MECP2
had an average correlation of 0.37, the closest enhancer
(53kb) had an expression correlation of 0.43, while the
highest correlated enhancer (r = 0.55) was over 408kb dis-
tant. For CDKL5, the only identified active enhancer had a
low correlation of 0.2 and was located over 245 kb up-
stream of the gene (Additional file 13: Table S6). Interest-
ingly, our data revealed that in humans, the only enhancer
displaying the expected high correlation with gene expres-
sion was for the tissue specific gene FOXG1.
CpG/TATA regulation of the three Rett genes and their
promoter shapes
To investigate the regulation of the promoters of the
three genes, we analyzed computationally, the presence
of CpG islands and TATA boxes in the vicinity of the
promoters of the three genes. Intersections of CpG and
TATA UCSC bed files, with our extracted list of TSSs,
revealed that the three genes had TATA-less promoters in
both species. Our data showed both promoters of MECP2
and CDKL5 within CpG islands in both species. For
FOXG1, 4 TSSs in mouse and 3 TSSs in human samples
appeared to be regulated by CpG islands (Table 2).
It is known that promoters regulated by TATA boxes
are ‘sharp’ where transcript initiation occurs at a well de-
fined dominant site, no more than 4 consecutive nucleo-
tides long, while promoters regulated by CpG islands are
‘broad’ where multiple start sites can be detected in a
Figure 3 Expression correlations between the three genes. Heat maps showing the TPM expression of all promoters in sub-regions of brain and brain
related primary cells in mouse (a) and humans (b). Expression of Mecp2 p1 appears to be in contrast with the expression of the main promoter of Foxg1 in
mouse (pA) and in humans (p1). The trees above the heatmaps show clustering according to expression. Plots in panels c to f show correlation between
the three genes in mouse (panels c and e) and human (panels d and f) as labeled. The expected negative correlation based on the heatmap between
MECP2 and FOXG1 could not be confirmed in either species across all samples (panels c and d). We found positive correlation (23-49%) between Cdkl5
and Mecp2 in both species (panels e and f).
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broad genomic region [48]. We analyzed the extracted
TSSs for sharp or broad shapes by aligning their expression
levels across the genomic locus. For our investigation, we
defined sharp promoters as those where the majority of the
transcripts start from a single dominant TSS or from
multiple TSSs within 5 nucleotides, while promoters were
classified as broad when they had multiple dominating ini-
tiation sites within a defined TSS cluster (maximum 50 bp
genomic window). We analyzed in humans and mouse,
the 3 main promoters for FOXG1 and two promoters each
for MECP2 and CDKL5. Our analyses revealed that the
main promoters for FOXG1 in both species (p1@FOXG1
and pA@Foxg1) were broad in keeping with the CpG
islands in their vicinity (Figure 5a, 5f). The second highest
expressed FOXG1 promoters in human and mouse
(p2@FOXG1 and pB@Foxg1) appeared to have species-
specific shapes and regulation. While p2@FOXG1 in
humans was found to be sharp with no TATA-box or
CpG island, pB@Foxg1 in mouse was broad and CpG
regulated (Figure 5b, 5g). In each species we found for
FOXG1, one sharp promoter (p3@FOXG1 and p1@foxg1)
devoid of TATA box or CpG island (Additional file 15:
Figures S9a,f).
The two main promoters of MECP2 were broad, in
agreement with the CpG islands near their TSS (Figure 5c,h
and Additional file 15: Figures S9e,l). In both species,
the promoter p1@CDKL5 was broad in shape while
p2@CDKL5 was sharp despite the presence of a CpG
Figure 4 Mouse gene models derived from FANTOM5 TSS and ENCODE ChIP data. Gene models for Foxg1 (panel a), Mecp2 (panel b) and
Cdkl5 (panel c) were drawn for the main TSS for each gene and the ENCODE histone ChIP marks for 8 week mouse cortex. For Foxg1, the enhancer
mark was 1 kb upstream and the promoter mark was 1.1 kb downstream of the TSS. For Mecp2, the TSS was upstream of the overlapping promoter
and enhancer mark. For Cdkl5, the TSS was within the promoter and the enhancer was upstream of the TSS.
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island in its vicinity (Figure 5d, e ,i and j). A comprehen-
sive list of promoters, their regulation and shapes is shown
in Table 2 and Additional file 15: Figure S9.
Transcriptional regulation of the three genes
To identify transcription factors binding to the three genes
in both species, we analyzed the genomic sequence within
500 bp from the promoters of the three genes using the
SwissRegulon database of sequence motifs associated with
transcription factors [49] (see Methods for details). We
found a putative binding site with a posterior probability
greater than 0.7 in the human FOXG1, MECP2 and
CDKL5 promoter regions for 23, 11 and 14 TFs respect-
ively (Additional file 16: Table S7A). Of these, binding
sites for the three transcription factors RREB1, FOXP1
and NFY were found in all three genes, suggesting that
the three genes implicated in Rett syndrome may be
regulated by the same TFs in humans. We then summed
the posterior probabilities over each promoter region to
estimate the number of binding sites for each transcrip-
tion factor and evaluated its statistical significance
(Table 3). The data reveal that in human, the sequence
around the main promoter of FOXG1 in human was sig-
nificantly enriched in binding sites for the RREB1 (p =
0.01), FOXP1 (p = 0.03), and NFY (p = 0.01) transcription
factors. NFY was also predicted to regulate MECP2 (p
= 0.01) and possibly CDKL5 (p = 0.09). Similar ana-
lyses in the mouse genome revealed motifs for 21, 5
and 3 TFs within 500 bp of the Foxg1, Mecp2 and
the Cdkl5 promoters respectively (Additional file 15:
Table S7B). In mouse although all TFs with binding
sites in the Mecp2 and Cdkl5 promoter regions also
appeared to have binding sites in the Foxg1 promoter re-
gion, only 2 TFs (Sp1 and NFY) were common to all
three genes. Calculating the statistical significance of
the estimated number of binding sites revealed that
in mouse for all three genes the promoter regions
were enriched for motifs associated with transcription
factor NFY, as well as Sp1 (Table 3).
Discussion
Our analyses of the FANTOM5 CAGE data reveal
multiple sites for transcript initiation and identify the
predominantly used TSSs of the three genes implicated in
RTT. Mutation testing for RTT is currently performed
solely on known coding exons, even though it has been
suggested that the non-coding regulatory regions may play
a role in the pathogenesis of RTT [50,51]. Our data show
that the highly used TSSs lie upstream of currently
annotated start sites and we propose that these regions be
included in testing to ensure accurate representation of
genes in diagnosis.
In our investigation we found the expression of FOXG1
strikingly in contrast with the expression of MECP2 in the
brain, but we could not get firm negative correlation
for this observation of discordance in expression. This
discrepancy may be due to the high expression level
of FOXG1 transcripts and the variable but comparatively
low-level expression of MECP2 mRNA in the brain.
Alternately, our visual observation may have resulted from
the fact that some brain regions in mouse (cerebellum and
medulla oblongata) and humans (locus coeruleus, pineal
gland, cerebellum, medulla oblongata and substantia nigra)
are clearly devoid of FOXG1 expression at any developmen-
tal stage. We further confirmed our observation of the
absence of Foxg1 expression in mouse cerebellum through
analyses of chromatin signatures from mouse ENCODE.
Our investigation revealed enrichment of H3K27me3 in the
Foxg1 genomic region, suggesting PRC2 mediated silencing
of Foxg1 in the cerebellum. Although H3K27me3 has also
been reported to be present at transcriptionally active or
Table 2 List of all transcript initiation sites for the 3
genes in mouse (A) and human (B) samples with their
shapes and association with TATA-box and CpG islands
A Mouse promoters
Promoter TATA CpG Shape
pA@Foxg1 TATA-less CpG Broad
pB@Foxg1 TATA-less CpG-less Broad
p1@Foxg1 TATA-less CpG-less Sharp
p2@Foxg1 TATA-less CpG Broad
p3@Foxg1 TATA-less CpG Broad
p4@Foxg1 TATA-less CpG Broad
p1@Mecp2 TATA-less CpG Broad
p2@Mecp2 TATA-less CpG Broad
p1@Cdkl5 TATA-less CpG Broad
p2@Cdkl5 TATA-less CpG Sharp
B Human promoters
Promoter TATA CpG Shape
p1@FOXG1 TATA-less CpG Broad
p2@ FOXG1 TATA-less CpG-less Sharp
p3@ FOXG1 TATA-less CpG-less Sharp
p4@ FOXG1 TATA-less CpG Broad
p5@ FOXG1 TATA-less CpG-less Broad
p6 @FOXG1 TATA-less CpG-less Broad
p7@ FOXG1 TATA-less CpG Broad
p9@ FOXG1 TATA-less CpG-less Sharp
p1@MECP2 TATA-less CpG Broad
p2@ MECP2 TATA-less CpG Broad
p5@MECP2 TATA-less CpG-less Broad
p1@CDKL5 TATA-less CpG Broad
p2@CDKL5 TATA-less CpG Sharp
Promoters were listed as TATA-less if a TATA-box was absent 500 bp upstream
of the promoter. Similarly in the absence of a CpG island within 500 bp of the
TSS, the promoter was classified as CpG-less.
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poised loci [52], the absence of active chromatin marks in
the Foxg1 promoter region in cerebellum but not in the
cortex, strongly suggest specific repression of Foxg1 in the
cerebellum. A similar examination in liver also revealed
H3K27me3 enrichment at the Foxg1 promoter region
(Additional file 4: Figure S2). It is tempting to propose
PRC2 mediated silencing as a universal mechanism to re-
strict Foxg1 expression to brain. It is known that PRC2 me-
diated silencing is facilitated through long ncRNAs [40],
but our screening did not reveal potential regulatory long
ncRNAs in the vicinity of Foxg1 suggesting such regulation
might be mediated by ncRNAs located outside our window
of investigation. It would be interesting to identify the long
ncRNAs involved in Foxg1 silencing and investigate their
contribution to the disease phenotype.
Despite the known discrepancy in mRNA and protein
levels of MECP2 [18,53]), we found that similar to
MeCP2 protein [54], MECP2 mRNA expression was low
in embryonic stages and high in adult stages in most brain
regions except the cerebellum, where its expression was
comparatively high in embryonic tissues as well. We also
examined the relation between Histone H1 and MECP2 at
the mRNA level. Our data show that in each brain related
sample, Histone H1 transcript expression is 10–1000 fold
greater than MECP2 transcript expression. Therefore, for
these gene transcripts to produce equal amounts of
protein, as suggested in Skene et al., massive up-regulation
of protein translation is required from MECP2 transcripts
or massive down-regulation of protein translation is
needed from Histone transcripts. Thus our data point to
another layer of regulatory control between transcription
and translation to equalize the protein output from low
expressed MECP2 transcripts and abundantly expressed
Histone H1 transcripts. The presence of inverted SINE
elements in the vicinity of promoters have been reported
to up-regulate protein translation [55] but we did not find
a similar configuration of SINE near theMECP2 promoter.
The MECP2 gene gives rise to two mRNA isoforms
with same transcription start site [56,57] and despite the
fact that our analyses revealed two TSSs for MECP2 in
Figure 5 Shapes of key promoters of the three genes. Promoter shapes were drawn for the key promoters of the three genes (panels a to j,
as labeled) based on the location of the first nucleotide in all tissues in mouse (panels a to e) and humans (panels f to j). Shape conservation is
seen across the two species in all promoters except pB of Foxg1 in mouse and p2 of FOXG1 in humans. Despite the closeness in location and
high correlation between p1 and p2 of CDKL5, we find variation in their shapes suggesting differential regulation in both species.
Table 3 Transcription factor binding sites analyses at the promoters of the three genes
TF p1@FOXG1 p2@FOXG1 p1@MECP2 p2@MECP2 p1@CDKL5 p2@CDKL5
RREB1 1.5 (p = 0.01)* 0.0 (p = 1.0) 0.0 (p = 1.0) 0.0 (p = 1.0) 0.7 (p = 0.08) 0.7 (p = 0.08)
FOXP1 1.3 (p = 0.03)* 0.7 (p = 0.1) 0.0 (p = 1.0) 0.0 (p = 1.0) 0.0 (p = 1.0) 0.0 (p = 1.0)
NFY 1.9 (p = 0.01)* 0.0 (p = 1.0) 1.3 (p = 0.02)* 1.9 (p = 0.01)* 0.9 (p = 0.09) 0.9 (p = 0.09)
TF pA@Foxg1 pB@Foxg1 p1@Mecp2 p2@Mecp2 p1@Cdkl5 p2@Cdkl5
RREB1 0.0 (p = 1.0) 0.9 (p = 0.06) 0.0 (p = 1.0) 0.34 (p = 0.6) 0.0 (p = 1.0) 0.0 (p = 1.0)
FOXP1 0.0 (p = 1.0) 0.0 (p = 1.0) 0.0 (p = 1.0) 0.2 (p = 0.7) 0.0 (p = 1.0) 0.0 (p = 1.0)
NFY 1.9 (p = 0.007)* 1.9 (p = 0.007)* 1.3 (p = 0.02)* 1.3 (p = 0.02)* 1.0 (p = 0.03)* 1.0 (p = 0.03)*
SP1 1.7 (p = 0.04)* 1.4 (p = 0.06) 2.5 (p = 0.01)* 2.5 (p = 0.01)* 2.6 (p = 0.01)* 2.6 (p = 0.01)*
*Denotes significant values.
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humans and mouse in all tissues, we could not allocate
two distinct start sites for the two isoforms of MECP2.
Based on our data, we were unable to conclude whether
p2@MECP2/Mecp2 represented an independent poorly
expressed protein coding isoform, a shorter non-coding
regulatory ncRNA transcript arising from the vicinity of
the main promoter p1@MECP2/Mecp2 or a tissue spe-
cific enhancer RNA (eRNA) [54] for MECP2. Almost
25% of all enhancers are expected to transcribe short
bi-directional capped transcripts called e-RNAs [54].
Our observations of stable low expression level of
p2@MECP2/Mecp2 sometimes below 5 TPM irrespective
of the expression level of p1@MECP2/Mecp2, its poor
correlation with p1@MECP2/Mecp2 expression and the
absence bi-directional transcripts at p2@MECP2/Mecp2,
do not support its identification as an e-RNA for MECP2.
The two TSSs for CDKL5 are highly correlated with each
other in mouse as well as humans. Based on their similar
expression levels and distinct promoter shapes, we
propose that they represent two independently regulated
transcripts despite their proximity.
The comparison between corresponding promoters in
human and mouse samples, including the novel promoter
p1@FOXG1 in human and pA@Foxg1 in mouse, revealed
remarkably similar shapes, suggesting evolutionary con-
servation in their regulation. The only exceptions were the
human p2@FOXG1 and pB@Foxg1 mouse, which due to
their distinctive promoter shapes appear to be regulated
in a species-specific manner.
The recently released ENCODE Histone ChIP seq data
[39], allowed us to distinguish, among our identified
TSS, active enhancers from active promoters [44,47] in
mouse. Despite the presence of enhancer specific histone
mark of H3K27ac, we could not find evidence of low-level
antisense transcripts at the enhancer marks in mouse
suggesting that enhancers at close range that do not
generate e-RNAs may regulate the three genes in
mouse. For human samples the histone ChIP data
were not available, but we found correlated e-RNAs
at distal locations from the TSSs. Our data suggest
that in humans the three genes may be regulated by
e-RNA producing enhancers at long range. It is unclear at
this stage whether this discrepancy reflects true species-
specific differences or if it reflects differences in data
analyses (Histone marks with no evidence of e-RNAs in
mouse vs e-RNAs alone in humans). Further experimental
validation is required to confirm whether these regions
identified in our study play a regulatory role in the
expression of the respective genes.
Almost 20% patients of atypical RTT do not have mu-
tations in the three genes. We conducted genome wide
TFBS analyses with the aim to discover the common
transcription factors likely to regulate the three genes
and thus identify shared pathways upstream. Mutations
or functional impairment of such common TFs may
affect the expression of the three genes, which may result
in disease phenotype. Our data predict that TFs NFY and
SP1 are likely to regulate FOXG1 and MECP2 but not
CDKL5 in humans and NFY is likely to regulate all three
genes in mouse. Further investigation will be needed to
experimentally verify these findings nevertheless, it will be
of interest to study the expression level and presence of
mutations in the common TFs in mutation negative RTT
patients.
Our investigations failed to demonstrate brain specific
promoter usage or particularly high levels of expression of
MECP2 in brain or neurons, which could have explained
the predominantly neurological phenotype seen in patients
with mutations in this ubiquitously expressed gene.
Conclusion
Our comprehensive analyses of data from the FANTOM5
project reveal novel insights into the common and distinct
genomic features of the three genes, which are related not
only by disease phenotype, but also in their regulation in a
species-specific manner.
Additional files
Additional file 1: Table S1. List of all tissues, cells and cell lines with
the TPM expression of the FANTOM5 defined transcription start sites of
the three genes shown per sample in sheets 1 and 2, and averaged TPM
expression across replicates shown in sheets 3 and 4.
Additional file 2: Table S2. List of RefSeq and FANTOM5 detected
transcription start sites in human and mouse.
Additional file 3: Figure S1. Top 15 samples in expression for each of
the three genes. Panels a, c and e represent mouse, while panels b,d and
f are human samples showing promoter expression in TPM, on X-axis, in
various tissues, as labeled on Y-axis. For each gene, the samples with the
highest expression of the main promoter (p1@FOXG1, p1@MECP2 and
p1@CDKL5 in human and pA@Foxg1, p1@Mecp2 and p1@Cdkl5 in mouse)
are shown. The expression of the other key promoters in these samples is
also shown (p2@FOXG1, p3@FOXG1, p2@MECP2 and p2@CDKL5 in human
and pB@Foxg1, p2@Mecp2 and p2@Cdkl5 in mouse).
Additional file 4: Figure S2. Silencing of Foxg1 in mouse. UCSC
Browser image of the genomic locus for Foxg1 showing ENCODE tracks
for DNAse-I hypersensitive sites, active enhancer specific histone mark
(H3K27ac), active promoter specific histone mark (H3K4me3) and PRC2
mediated repressor mark (H3K27me3) in mouse cerebellum, cerebrum,
whole brain and liver as labeled. Cerebellum samples lack the DNAse-I
hypersensitive sites visible in cerebrum and whole brain samples.
Cerebellum samples also lack the active promoter mark H3K4me3 seen in
cortex, but contain PRC2 repressive histone mark H3K27me3 not seen in
cortex at the locus.
Additional file 5: Figure S3. Expression levels of Mecp2 and Cdkl5
during development in heart kidney and liver. The line plots show the
fluctuations in expression for the two promoters for Mecp2 and Cdkl5 in
heart, (a and d), kidney (b and e) and liver (c and f) in mouse.
Additional file 6: Figure S5. Developmental profile for the 3 genes in
human brain. Human FOXG1 (a), MECP2 (b) and CDKL5 (c) expression in
TPM across a set of adult, newborn and fetal brain regions is shown as
labeled. FOXG1 shows the highest overall expression as well as having
higher expression in fetal than in adult samples as opposed to the
expression of MECP2 and CDKL5 in the same samples.
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Additional file 7: Figure S4. Expression profile of the three genes in
mouse in developing brain tissues. Line plots showing expression of
selected promoters of Foxg1, Mecp2 and Cdkl5 during development in
mouse cerebellum (panel a), mouse visual cortex (panel b) and mouse
pituitary gland (panel c). Refer main text for details.
Additional file 8: Figure S6. Comparison of mRNA levels of Histone H1
and MECP2. Bar charts showing TPM expression of the key promoter of
MECP2 and collective total expression of Histone H1 TSSs in brain related
cells (panels a and c) and tissues (panels b and d) in mouse (panels a and b)
and humans (panels c and d). Histone expression levels appear to be over
100 fold higher than MECP2 in brain related cells suggesting a massive
up-regulation of MeCP2 at the level of protein translation.
Additional file 9: Table S3. Comparison of the expression of the
Histone H1 genes promoters and MECP2 in both human and mouse.
Additional file 10: Table S4. Pearson and Spearman correlations for all
TSSs in human and mouse.
Additional file 11: Figure S7. Intra and inter gene expression
correlations between the three genes. Expression correlation plots for all
other promoter combinations not present in Figure 3. Plots a-g are
mouse promoters, while plots h-n are human promoters as labeled.
Additional file 12: Table S5. Location of enhancer and promoter
specific Histone marks in relation to TSSs in mouse.
Additional file 13: Table S6. Locations and correlations of human
enhancers to the three Rett genes.
Additional file 14: Figure S8. Locations of active enhancers correlated
to the three genes in human samples. UCSC snapshot showing the
positions of all eRNA producing human enhancers that are correlated to
the expression of the three genes: FOXG1 (a), MECP2 (b) and CDKL5 (c).
Additional file 15: Figure S9. Promoter shapes for all the other
promoters. The shapes of all the individual promoters in mouse (a-e) and
human (f-m) are shown as labeled. The shapes are drawn from the first
nucleotide of the first mapped CAGE tag to the first nucleotide of the last
mapped CAGE tag, the y-axis shows the counts in TPM for each position.
Additional file 16: Table S7. List of transcription factors with high
binding probability of 0.7 and above to the promoters of the three genes
in mouse (A) and human (B) genome. Transcription factors common to
the three genes are shown in red.
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